SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-123925
Filing Date
2023-12-06
Accepted
2023-12-06 14:35:41
Documents
14
Period of Report
2023-12-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2332252d1_8k.htm   iXBRL 8-K 51736
2 EXHIBIT 99.1 tm2332252d1_ex99-1.htm EX-99.1 13556
3 EXHIBIT 99.2 tm2332252d1_ex99-2.htm EX-99.2 13786
  Complete submission text file 0001104659-23-123925.txt   261267

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA acur-20231204.xsd EX-101.SCH 3021
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE acur-20231204_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acur-20231204_pre.xml EX-101.PRE 22363
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2332252d1_8k_htm.xml XML 3224
Mailing Address 616 N. NORTH COURT, SUITE 120 . PALATINE IL 60067
Business Address 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067 847-705-7709
ACURA PHARMACEUTICALS, INC (Filer) CIK: 0000786947 (see all company filings)

IRS No.: 110853640 | State of Incorp.: NY | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-10113 | Film No.: 231469185
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences